Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Robust biomarker binders, probes and assays for sustainable precision medicine

Project description

Smarter diagnostics to reduce cancer disparities

Cancer survival rates vary. Disparities exist throughout the entire cancer care process, from prevention to diagnosis, treatment, and end-of-life care. This often occurs because of unequal access to tests, treatments, and specialised clinics. Supported by the Marie Skłodowska-Curie Actions programme, the MIPrecise project aims to develop diagnostic platforms using stable imprinted polymers. The goal is to detect cancer earlier and make advanced testing more accessible to patients. The project will train doctoral candidates in modern methods for finding biomarkers, liquid biopsies, and personalised cancer treatments, along with business and entrepreneurial skills. Overall, MIPrecise seeks to reduce inequalities in cancer care.

Objective

Cancer treatment outcomes vary widely due to inequalities in access to tests, drugs and the need for regular visits to specialist clinics. Many limitations can be addressed by developing more sensitive and robust tests for underexploited cancer biomarkers that can detect cancer sooner, be deployed in local clinics and simplify sample shipment and storage. Such tests will improve health outcomes, and also reduce the substantial environmental impact of biological reagent manufacture and patient travel. MIPrecise is an innovative and integrative network for training of doctoral candidates (DCs) that aims to address these challenges by re-engineering the diagnostic development and delivery pipeline through use of inexpensive, highly stable imprinted polymers. Training a new generation of doctoral scientists in methods that can develop and transition the novel diagnostic and monitoring platforms is crucial, for sustainable development and future impact for cancer patients. Through four work packages MIPrecise will make progress related to the following cancer relevant topics:

- Assays for guiding personalized therapies based on kinase inhibitors
- Robust assays and home based sampling for small cell lung cancer
- Discovery of new biomarkers for more precise cancer diagnostics
- Fast and sensitive liquid biopsies for assessment of tumour aggresiveness

The project will give 13 DCs a first-class interdisciplinary and intersectorial training program that combines scientific excellence with important transferable, business and entrepreneurial skills. This meets needs for highly skilled researchers supporting a competitive MedTech sector in Europe. 12 leading groups in the field of molecular imprinting, smart materials, proteomics, single cell analysis and clinical diagnostics at 8 universities, 1 research institute and 3 companies will form an inter-disciplinary expert network to develop disruptive greener technologies to address inequalities in cancer care.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-DN - HORIZON TMA MSCA Doctoral Networks

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2024-DN-01

See all projects funded under this call

Coordinator

MALMO UNIVERSITET
Net EU contribution
€ 649 260,00
Address
NORDENSKIOLDSGATAN 1
205 06 MALMOE
Sweden
Region
Östra Sverige Stockholm Stockholms län
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Participants (9)

Partners (3)